China's WuXi Biologics to sell Irish vaccine facility to Merck as US curbs loom
China's WuXi Biologics said on Monday it will sell its vaccine facility in Ireland to U.S. drugmaker Merck & Co for about ...
WuXi Bio to Sell Vaccine Facility to Merck for $500 Million
WuXi Biologics Cayman Inc. will sell a vaccine facility in Ireland to Merck & Co. for about $500 million as the Chinese ...
China's WuXi Biologics to sell Ireland vaccine facility to Merck for $500 million
The Financial Times had reported in October, citing people familiar with the matter, that WuXi and WuXi AppTec are planning ...
WuXi Biologics to Sell Irish Vaccine Facility to Merck for $500 Million
WuXi Biologics’ move to sell the facility could strengthen the company’s cash flow and margins as it navigates global ...
Merck launches first-to-market, cyber-physical trust platform to tackle issues of product safety and counterfeiting
M-Trust is a secure cyber-physical trust platform that enables the creation of digital twins for enhanced product quality and ...
Chinese Cat Owners Are Feeding Covid-19 Pills To Their Pets. Here's Why
Merck & Co.'s Covid-19 antivirals are getting a new lease of life in post-pandemic China, as cat owners seize on them as ...
China's WuXi Biologics to sell Irish vaccine facility to Merck for $500 million
China's WuXi Biologics said on Monday it will sell its vaccine facility in Ireland to U.S. drugmaker Merck & Co for about ...
Business Insider22d
China Approves Merck's Keytruda To Treat Patients With Resectable Stage II, IIIA Or IIIB NSCLC
(RTTNews) - Merck & Co Inc. (MRK), Monday said China's National Medical Products Administration (NMPA) has approved Keytruda in combination with chemo therapy as neoadjuvant treatment, then as ...
Business Insider7d
Merck’s sotatercept approved by MHRA to treat PAH
The new marketing authorization was granted on December 27 to Merck (MRK) Sharp & Dohme Limited. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news.
UPI19d
Merck reaches weight-loss drug deal worth up to $2 billion with China-based Hansoh
Dec. 18 (UPI) --Merck announced a weight loss drug deal Wednesday with China-based Hansoh worth up to $2 billion for the pill code-named HS-10535. It includes an upfront $112 million licensing ...
Investing22d
Merck's KEYTRUDA gains new approval in China for early-stage lung cancer treatment
RAHWAY, N.J. - Merck (NS:PROR) (NYSE: MRK), known as MSD outside the United States and Canada, has received approval from the National Medical (TASE:PMCN) Products Administration (NMPA) in China ...
Reuters20d
Merck signs up to $2 billion deal for oral weight-loss drug with China's Hansoh
Dec 18 (Reuters) - Merck (MRK.N), opens new tab has signed a licensing deal worth up to $2 billion for Chinese biotech Hansoh Pharma's (3692.HK), opens new tab experimental oral drug to treat ...